Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MYOC | Q99972 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL514113 | 0.84 | KMT2A (0.65) | KMT2AMEN1MAPTNPC1MAPK1 | |
| SCHEMBL9994168 | 0.83 | MAPT (0.60) | KMT2AMEN1MAPTNPC1MAPK1 | |
| SCHEMBL513489 | 0.83 | KMT2A (0.59) | KMT2AMEN1MAPTNPC1MAPK1 | |
| SCHEMBL1532248 | 0.83 | KMT2A (0.59) | KMT2AMEN1MAPTNPC1MAPK1 | |
| SCHEMBL2071222 | 0.83 | KMT2A (0.63) | KMT2AMEN1MAPTNPC1MAPK1 | |
| SCHEMBL3573967 | 0.82 | MAPT (0.66) | KMT2AMEN1MAPTNPC1MAPK1 | |
| SCHEMBL2233218 | 0.82 | ALDH1A1 (0.56) | KMT2AMEN1MAPTNPC1MAPK1 | |
| SCHEMBL9609808 | 0.82 | SMN1; SMN2 (0.82) | KMT2AMAPTNPC1RAB9AGAA | |
| SCHEMBL642700 | 0.81 | KMT2A (0.81) | KMT2AMEN1MAPTNPC1MAPK1 | |
| SCHEMBL16922176 | 0.81 | KMT2A (0.81) | KMT2AMEN1MAPTNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023210623-A1 | HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME | 株式会社エス・ディー・エス バイオテック | 2023-11-02 | — | — | WO | disclosed |
| US-20230279019-A1 | BENZONORBORNADIENE DERIVATIVES AND REACTIONS THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2023-09-07 | — | — | US | disclosed |
| US-11560384-B2 | Benzonorbornadiene derivatives and reactions thereof | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-01-24 | — | — | US | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-113166102-A | Anticancer compounds | 法马马有限公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3508473-B1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | AIST (JP) | 2021-05-26 | — | — | EP | disclosed |
| US-10752579-B2 | Production method of carbamic acid ester | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-08-25 | — | — | US | disclosed |
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2019-09-26 | — | — | US | disclosed |
| EP-3508473-A1 | METHOD FOR PRODUCING CARBAMIC ACID ESTER | National Institute of Advanced Industrial Science and Technology (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20090221515-A1 | MONOSACCHARIDE DERIVATIVES | RANBAXY LABORATORIES INC. (IN) | 2009-09-03 | — | — | US | disclosed |
| CN-1330652-C | Novel carbapenem compounds | SUMITOMO PHARMA (JP) | 2007-08-08 | — | — | CN | disclosed |
| US-7205291-B2 | High mouth absorption; antibiotics against gramnegative, grampositive bacteria espscially Staphlococcus pneumonia, Hemophilus influenza | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| CN-1612879-A | Novel carbapenem compounds | SUMITOMO PHARMA (JP) | 2005-05-04 | — | — | CN | disclosed |
| US-20050020566-A1 | Novel carbapenem compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1443047-A1 | NOVEL CARBAPENEM COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-08-04 | — | — | EP | disclosed |
| CN-1518445-A | Treatment of sexual dysfunction | 沃纳-兰伯特公司 | 2004-08-04 | — | — | CN | disclosed |
| CN-1479618-A | Treatment of sexual dysfunction with bombesin antagonists | ����-�����ع�˾ | 2004-03-03 | — | — | CN | disclosed |
| US-4410697-A | CARBAMATE, AMINE, TERTIARY AMINE CATALYST | REANAL FINOMVEGYSZERGYAR (HU) | 1983-10-18 | — | — | US | disclosed |
| WO-1981002156-A1 | PROCESS FOR THE PREPARATION OF N-ARYL-N'-(MONO-OR DISUBSTIUTED)-UREA DERIVATIVES | REANAL FINOMVEGYSZERGYAR (HU) | 1981-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020566-A1 | Novel carbapenem compounds | HPN, PRSS1, BPGM | KMT2A 2782/4885MEN1 3435/4885MAPT 3098/4885 |
| US-10745364-B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | RORB, RORA, RORC | KMT2A 1531/4885MEN1 2840/4885MAPT 3622/4885 |
| US-20230279019-A1 | BENZONORBORNADIENE DERIVATIVES AND REACTIONS THEREOF | CBR3, CBR1, CNR1 | KMT2A 3923/4885MEN1 2994/4885MAPT 4885/4885 |
| US-20090221515-A1 | MONOSACCHARIDE DERIVATIVES | HLA-DRB1, MUC1, FUT5 | KMT2A 3928/4885MEN1 1520/4885MAPT 1370/4885 |
| US-20190292159-A1 | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | KMT2A 1531/4885MEN1 2840/4885MAPT 3622/4885 |
| US-11560384-B2 | Benzonorbornadiene derivatives and reactions thereof | CBR3, CBR1, CNR1 | KMT2A 3784/4885MEN1 2865/4885MAPT 4877/4885 |
| US-10752579-B2 | Production method of carbamic acid ester | CA2, CA7, CA4 | KMT2A 243/4885MEN1 2437/4885MAPT 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.